COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study

Abstract

Objectives COVID-19 vaccines have been proven to be safe in the healthy population. However, gaps remain in the evidence of their safety in patients with systemic autoimmune and inflammatory disorders (SAIDs). COVID-19 vaccination related adverse events (ADEs) in patients with SAIDs and healthy controls (HC) seven days post-vaccination were assessed in the COVAD study, a patient self-reported cross-sectional survey. Methods The survey was circulated in early 2021 by > 110 collaborators (94 countries) to collect SAID details, COVID-19 vaccination details, and 7-day vaccine ADEs, irrespective of respondent vaccination status. Analysis was performed based on data distribution and variable type. Results 10900 respondents [42 (30-55) years, 74% females and 45% Caucasians] were analyzed. 5,867 patients (54%) with SAIDs were compared with 5033 HCs. 79% had minor and only 3% had major vaccine ADEs requiring urgent medical attention (but not hospital admission) overall. Headache [SAIDs=26%, HCs=24%; OR = 1.1 (1.03-1.3); p = 0.014], abdominal pain [SAIDs=2.6%, HCs=1.4%; OR = 1.5 (1.1-2.3); p = 0.011], and dizziness [SAIDs=6%, HCs=4%; OR = 1.3 (1.07-1.6); p = 0.011], were slightly more frequent in SAIDs. Overall, major ADEs [SAIDs=4%, HCs=2%; OR = 1.9 (1.6-2.2); p < 0.001] and, specifically, throat closure [SAIDs=0.5%, HCs=0.3%; OR = 5.7 (2.9-11); p = 0.010] were more frequent in SAIDs though absolute risk was small (0-4%). Major ADEs and hospitalizations (less than 2%) were comparable across vaccine types in SAIDs. Conclusion Vaccination against COVID-19 is relatively safe in SAID patients. SAIDs were at a higher risk of major ADEs than HCs, though absolute risk was small. There are small differences in minor ADEs between vaccine types in SAID patients.

Coronavirus disease 2019 vaccination uptake and hesitancy among Polish patients with inborn errors of immunity, autoinflammatory syndromes, and rheumatic diseases: A multicenter survey

“…Some studies evaluated the specific patient concerns related to the COVID-19 vaccine, which included unknown long-term side effects, the newness of the COVID-19 vaccine, and the perception of rushed development and introduction with potential financial links to the pharmaceutical companies ( 9 , 18 , 24 , 26 ). Those unvaccinated also feared that the vaccine would be harmful and could cause thrombosis ( 24 ), despite well-documented contrary evidence ( 43 ). Furthermore, a concern about potential side effects is a well-documented primary argument against COVID-19 vaccination among the general Polish population ( 3 ) and health care workers, especially nurses ( 4 ).…”

COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis

“…We have recently reported vaccine safety in idiopathic inflammatory myopathies (IIMs) using data from the global COVID-19 vaccination in autoimmune diseases (COVAD) study initiative, demonstrating the overall benefit of vaccination in this group of individuals (7,8). However, in this study, we observed a greater predisposition to specific adverse events, such as skin rashes in certain IIM subgroups, particularly the dermatomyositis subgroup and those with active inflammatory disease, such as the inclusion body myositis subgroup (7).…”

An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations

“…An 82 year old woman with signs of general discomfort and body pain after a week of receiving the vaccine was the first case that showed the association between the GBS and vaccination [130] . In addition, clinical signs related to the GBS and the vaccines from Janssen and ChAdOx1-S/nCoV-19 were observed in India and England [130] , [131] .…”